Behçet DiseaseNCT07845162
Serum EBI-3 Protein Levels in Behçet's Disease
An observational study of Behçet Disease, run by Assiut University.
Trial summary
This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Behçet Disease
- How many people
- 90 participants
- Where
- No sites listed yet
- Study dates
- 26 Sep 2026to 25 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients with Behçet's disease attending the Physical Medicine, Rheumatology and Rehabilitation Department at Assiut University Hospitals, and healthy controls.
Who may be able to join
- - Age 18 years or older
- Diagnosis of Behçet's disease according to the International Criteria for Behçet's Disease (cases)
- Healthy individuals without autoimmune or inflammatory diseases (controls)
- Written informed consent
Who cannot join
- - Other autoimmune disorders (RA, SLE, psoriatic arthritis, ankylosing spondylitis)
- Acute or chronic infection
- Malignancy or history of malignancy
- Chronic liver disease or advanced chronic kidney disease
- Pregnancy or lactation
- Vasculitis caused by diseases other than Behçet's disease
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Serum Epstein-Barr Virus-induced Gene 3 Protein Levels in Patients With Behçet's Disease
This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.
Read the detailed description
Behçet's disease is a chronic multisystem inflammatory disorder. Serum EBI-3 protein levels may reflect inflammatory activity.
This observational study will include adult patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease and age-matched healthy controls. Serum EBI-3 protein levels will be measured by ELISA.
- Conditions
- Behçet Disease
- Keywords
- Behçet's disease, EBI-3 Serum, biomarker, Assiut
- Medical subject headings
- Behcet Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Behçet's Disease | Patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease. | |
| Healthy Controls | Age-matched healthy individuals without autoimmune or inflammatory diseases. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean serum EBI-3 protein level
Mean serum Epstein-Barr virus-induced gene 3 (EBI-3) protein concentration measured by ELISA in patients with Behçet's disease compared with healthy controls.
Measured: Baseline
Secondary outcomes (4)
Serum EBI-3 level according to disease activity
Mean serum EBI-3 protein concentration according to Behçet's Disease Current Activity Form (BDCAF) score.
Measured: Baseline
Serum EBI-3 level in patients with vascular involvement
Mean serum EBI-3 protein concentration in patients with and without vascular involvement
Measured: Baseline
Serum EBI-3 level in patients with ocular involvement
Mean serum EBI-3 protein concentration in patients with and without ocular involvement.
Measured: Baseline
Serum EBI-3 level in patients with neurological involvement
Mean serum EBI-3 protein concentration in patients with and without neurological involvement.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2026
- Study start26 Sep 2026 (estimated)
- Primary completion26 Sep 2027 (estimated)
- Study completion25 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Behçet DiseaseStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shrouk Samir Mohamed, Assiut University
- Investigators
- Gehan I Abdelraziq, prof, Study chair, Physical Medicine, Rheumatology and Rehabilitation Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07845162
- Sponsor's protocol ID
- EBI3-Behcet-Assiut-2026
- Status last verified
- Sep 2026
- First submitted
- 22 Sep 2026
- Last updated
- 28 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum Epstein-Barr Virus-induced Gene 3 Protein Levels in Patients With Behçet's Disease
- ClinicalTrials.gov ID
- NCT07845162
- Acronym / sponsor ID
- EBI3-Behcet-Assiut-2026
- Conditions
- Behçet Disease
- Keywords
- Behçet's disease, EBI-3 Serum, biomarker, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 26 Sep 2026 (estimated)
- Primary completion
- 26 Sep 2027 (estimated)
- Study completion
- 25 Jan 2028 (estimated)
- First posted
- 28 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.
Detailed description
Behçet's disease is a chronic multisystem inflammatory disorder. Serum EBI-3 protein levels may reflect inflammatory activity.
This observational study will include adult patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease and age-matched healthy controls. Serum EBI-3 protein levels will be measured by ELISA.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Behçet's Disease | – | –Patients diagnosed with Behçet's disease according to the International Criteria for Behçet's Disease. |
| Healthy Controls | – | –Age-matched healthy individuals without autoimmune or inflammatory diseases. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with Behçet's disease attending the Physical Medicine, Rheumatology and Rehabilitation Department at Assiut University Hospitals, and healthy controls.
Key inclusion criteria (4 listed)
- - Age 18 years or older
- Diagnosis of Behçet's disease according to the International Criteria for Behçet's Disease (cases)
- Healthy individuals without autoimmune or inflammatory diseases (controls)
- Written informed consent
Key exclusion criteria (6 listed)
- - Other autoimmune disorders (RA, SLE, psoriatic arthritis, ankylosing spondylitis)
- Acute or chronic infection
- Malignancy or history of malignancy
- Chronic liver disease or advanced chronic kidney disease
- Pregnancy or lactation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mean serum EBI-3 protein level
Time frame: Baseline
Mean serum Epstein-Barr virus-induced gene 3 (EBI-3) protein concentration measured by ELISA in patients with Behçet's disease compared with healthy controls.
4 secondary outcomes
Serum EBI-3 level according to disease activity
Time frame: Baseline
Serum EBI-3 level in patients with vascular involvement
Time frame: Baseline
Serum EBI-3 level in patients with ocular involvement
Time frame: Baseline
Serum EBI-3 level in patients with neurological involvement
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Behçet Disease
Not yet recruitingObservational study
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
RecruitingPhase 3
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Behçet Disease
Recruiting
Deployment o the Multidisciplinary Prospective Cohort Imminent
Chronic Inflammatory Disease, Angioedema
Active, not recruitingPhase 4
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Rheumatoid Arthritis, Spondylitis, Ankylosing
Recruiting
Clinical, Biochemical and Epigenetic Profile of Pediatric Behçet Disease
Behcet Disease and Vascular Involvement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gehan I Abdelraziq, prof study chair
Physical Medicine, Rheumatology and Rehabilitation Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Behçet Disease, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shrouk S Mohamed, Resident (01004638754, shrouk.18313202@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean serum EBI-3 protein level (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.